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proliferator-activated receptor α (PPARα) in
different mouse liver models identify novel
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Abstract
Background: The peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated transcription factor
that regulates lipid catabolism and inflammation and is hepatocarcinogenic in rodents. It is presumed that the
functions of PPARα in liver depend on cross-talk between parenchymal (hepatocytes) and non-parenchymal
(Kupffer and endothelial cells) fractions as well as inter-organ interactions. In order to determine how cellular
composition and inter-organ interactions influence gene expression upon pharmacological activation of PPARα, we
performed a meta-analysis of transcriptomics data obtained from mouse hepatocytes (containing only the parenchymal
fraction), mouse liver slices (containing both fractions), and mouse livers exposed to a PPARα agonist. The aim was to
obtain a comprehensive view of common and model-specific PPARα-dependent genes and biological processes to
understand the impact of cross-talk between parenchymal and non-parenchymal fractions as well as the effect of
inter-organ interactions on the hepatic PPARα transcriptome.
To this end we analyzed microarray data of experiments performed in mouse primary hepatocytes treated with the
PPARα agonist Wy14643 for 6 or 24 h (in vitro), mouse precision cut liver slices treated with Wy14643 for 24 h (ex vivo),
and livers of wild type and Ppara knockout mice treated with Wy14643 for 6 h or 5 days (in vivo).
Results: In all models, activation of PPARα significantly altered processes related to various aspects of lipid metabolism.
In ex vivo and in vivo models, PPARα activation significantly regulated processes involved in inflammation; these
processes were unaffected in hepatocytes. Only in vivo models showed significant regulation of genes involved in
coagulation, carcinogenesis, as well as vesicular trafficking and extracellular matrix.
Conclusions: PPARα-dependent regulation of genes/processes involved in lipid metabolism is mostly independent of
the presence of non-parenchymal cells or systemic factors, as it was observed in all liver models. PPARα-dependent
regulation of inflammatory genes requires the presence of non-parenchymal cells, as it was observed only ex vivo and
in vivo. However, the full spectrum of PPARα biology at the level of lipid metabolism, immunity, carcinogenesis, as well
as novel aspects of PPARα signaling such as coagulation, vesicular trafficking and the extracellular matrix, seems to
require systemic factors, as it was observed exclusively in vivo.
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Background
Peroxisome proliferators, which include insecticides,
herbicides, surfactants, phthalates, organic solvents, and
hypolipidemic/anti-inflammatory fibrate drugs, were dis-
covered as chemicals that upon administration to rodents
increase the number of liver peroxisomes, stimulate fatty
acid catabolism, and after chronic exposure cause hepato-
megaly and hepatocarcinogenesis [1]. The effects of per-
oxisome proliferators are mediated by the peroxisome
proliferator-activated receptor α (PPAR α) [2]. PPARα, to-
gether with PPARδ and PPARγ, forms a small subfamily of
PPARs within the superfamily of nuclear receptors [3].
Similarly to other nuclear receptors, PPARα acts as a
heterodimer with the retinoid X receptor and occupies
specific DNA sequences referred to as PPAR response ele-
ments. Binding of a ligand to PPARα leads to the dissoci-
ation of co-repressors and the association of co-activators
necessary for the activation of transcription. In mice,
PPARα has the highest expression level in liver and brown
adipose tissue, followed by a lower expression in kidney,
heart, and intestine [4]. The physiological role of PPARα
in liver is to govern lipid metabolism. In particular during
starvation, activation of PPARα leads to stimulation of
fatty acid (FA) uptake, mitochondrial β-oxidation, peroxi-
somal FA oxidation, and ketogenesis [5,6]. In addition,
PPARα controls lipoprotein metabolism [7-10]. Due to the
role of PPARα in maintenance of lipid homeostasis, it has
become an important molecular target for dyslipidemia
[11]. In addition, PPARα ligands and dual PPARα/PPARδ
ligands are being explored for the treatment of non-
alcoholic fatty liver disease [12].
Apart from its profound role in regulation of lipid
metabolism, PPARα exerts anti-inflammatory and anti-
atherogenic effects, which may be beneficial in the treat-
ment of several metabolic diseases associated with
inflammation such as non-alcoholic steatohepatitis and
atherosclerosis [11,13]. The anti-inflammatory actions of
PPARα are mediated via its negative interference with
other nuclear factors such as the NF-κB, AP-1, C/EBP,
and STAT proteins, which govern innate and adaptive
immunity [14,15]. In the liver, hepatocytes likely are the
major cell type mediating the anti-inflammatory effects
of PPARα, since no PPARα was detected in rat liver resi-
dent macrophages i.e. Kupffer cells [16,17]. In addition
to hepatocytes, PPARα is expressed in other relevant im-
mune cells such as dendritic cells, non-hepatic macro-
phages, as well as B and T lymphocytes, which can
infiltrate the liver during development of metabolic dis-
orders. Accordingly, these cells are potential therapeutic
targets for PPARα ligands to manage hepatic inflamma-
tion [18-20]. PPARα is also expressed in non-hepatic
vascular cells, likely accounting for the effects of syn-
thetic PPARα agonists on angiogenesis [21,22], endothe-
lial permeability [23], and vascular adhesion capacity
[11], which are important in the treatment of athero-
sclerosis. However, it is questionable whether PPARα ag-
onists can directly affect hepatic endothelial cell gene
expression, because mouse and rat endothelial cells do
not express PPARα [16,17,24].
Although PPARα is expressed in the liver parenchymal
fraction (i.e. hepatocytes) and is not or very weakly
expressed in the rodent non-parenchymal liver fraction
(i.e. Kupffer cells and endothelial cells) [16,17,24], it is
presumed that interactions between both fractions as
well as inter-organ interactions are necessary to fulfill
hepatic PPARα functions related to regulation of lipid
metabolism and immunity. In order to determine how
cellular composition and inter-organ interactions influ-
ence gene expression upon PPARα activation, we per-
formed a meta-analysis of transcriptomics data obtained
from relevant mouse liver models represented by mouse
primary hepatocytes (containing only the parenchymal
fraction) treated with the PPARα agonist Wy14643 for 6
or 24 h (in vitro), precision cut liver slices (containing
both parenchymal and non-parenchymal fractions) treated
with Wy14643 for 24 h (ex vivo), and livers of wild type
(WT) and Ppara knockout (KO) mice treated with
Wy14643 for 6 h or 5 days (in vivo). The aim was to ob-
tain a comprehensive view of common and model-specific
PPARα-dependent genes and biological processes to
understand the impact of the cross-talk between paren-
chymal and non-parenchymal fractions as well as the ef-
fect of inter-organ interactions on the hepatic PPARα
transcriptome. In addition, we aimed to assess the per-
formance of in vitro and ex vivo liver models to study the
PPARα transcriptome in relation to the in vivo situation.
Methods
Chemicals
Wy14643 was obtained from ChemSyn Laboratories
(Lenexa, KS). Recombinant human insulin (Actrapid) was
obtained from Novo Nordisk (Copenhagen, Denmark).
DMEM, fetal calf serum, calf serum, and penicillin/
streptomycin/fungizone were obtained from Lonza Bio-
science (Verviers, Belgium). Williams E medium supple-
mented with Glutamax, penicillin/streptomycin (pen/strep),
D-glucose, phosphate buffered saline (PBS) were obtained
from Invitrogen (Invitrogen, Bleiswijk, The Netherlands).
Otherwise, chemicals were obtained from Sigma
(Zwijndrecht, The Netherlands).
Mouse primary hepatocytes (in vitro liver model)
Mouse hepatocytes were prepared and used in experi-
ments have been described previously [25]. Briefly, the
hepatocytes were isolated by two-step collagenase perfu-
sion from 6 different strains of mouse; NMRI, SV129,
FVB, DBA, BALB/C and C57BL/6. The mouse strains
differed with respect to age (2–6 months) and gender
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(female or male) [25]. Cells were plated on collagen-
coated six-well plates. Cell viability was determined by
Trypan Blue exclusion, and was at least 75%. Hepatocytes
obtained for 6 different mouse strains were cultured inde-
pendently in William’s E medium (Lonza Bioscience,
Verviers, Belgium) supplemented with 10% (v/v) fetal calf
serum, 20 m-units/mL insulin, 10 nM dexamethasone,
100 U/mL penicillin, 100 mg/mL of streptomycin, 0.25
mg/mL fungizone and 50 mg/mL gentamycin. After four
hours the medium was discarded and replaced with fresh
medium. The next day, cells were incubated in fresh
medium in the presence or absence of Wy14643 (10 μM)
dissolved in dimethyl sulfoxide (DMSO) for 6 and 24 h,
followed by RNA isolation. Isolation of mouse primary he-
patocytes was approved by the Ethical Committee for Ani-
mal Experiments of Wageningen University.
Precision cut liver slices (ex vivo liver model)
Precision cut liver slices (PCLS) were prepared and cul-
tured as described previously [26]. Briefly, livers from 6
months old C57BL/6 mice were perfused with saline, ex-
cised and submerged in ice-cold Krebs-Henseleit Buffer
(KHB) supplemented with 11 mM glucose, 25 mM sodium
bicarbonate, 10 mM 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid (HEPES), and penicillin/streptomycin. The
livers were collected at ~11 a.m. (ZT5). Next, 5 mm cylin-
drical liver cores were prepared with a surgical biopsy
punch and sectioned to 200 μm slices using a Krumedieck
tissue slicer (Alabama Research and Development,
Munford, AL, USA) filled with carbonated KHB. Liver
slices were incubated in William’s E Medium (Lonza,
Verviers, Belgium) in 6-well plates at 37°C/5% CO2/80%
O2 under continuous shaking. After 1 hour the media was
replaced with fresh William’s E Medium in the presence
or absence of Wy14643 (20 μM) dissolved in dimethyl
sulfoxide (DMSO). After 24 h incubation, samples were
snap-frozen in liquid nitrogen and stored in −80°C for
RNA isolation. PCLS were obtained from four mice and
were cultured independently per each experimental condi-
tion i.e. n = 4 for Wy14643 and n = 4 for DMSO.
Animals (in vivo liver model)
In vivo treatment with Wy4643 has been described pre-
viously [27]. Briefly, male wildtype and Ppara-KO mice
on a Sv129 background were used at 3–5 months of age
(Jackson Laboratories, Bar Harbor, ME). Animals were
fed normal laboratory chow (RMH-B diet, Arie Blok ani-
mal feed, Woerden, the Netherlands). During acute
pharmacological activation of PPARα by Wy14643, wild-
type and Ppara-KO mice fasted for 4 hours received a
single dose of Wy14643 (400 μL of 10 mg/mL Wy14643
dissolved in 0.5% carboxymethylcellulose) and were
killed 6 hours later (n = 5 per group). During chronic
pharmacological activation of PPARα by Wy14643, WT
and Ppara-KO mice were fed with Wy14643 for 5 days
by mixing it in their food (0.1%, n = 5 per group). Livers
from the acute pharmacological activation of PPARα
were collected at ~3 p.m. (ZT9) and livers from the
chronic activation of PPARα were collected at ~11 a.m.
(ZT5). Livers from all experiments were dissected and im-
mediately frozen in liquid nitrogen for RNA isolation. All
animal experiments were approved by the Ethical Com-
mittee for Animal Experiments of Wageningen University.
RNA isolation
Total RNA was extracted from primary hepatocytes using
TRIzol reagent (Invitrogen, Breda, The Netherlands) and
RNA was further purified using RNeasy micro columns
(Qiagen, Venlo, the Netherlands).
Prior to RNA isolation, PCLS were homogenized with
a tissue homogenizer Precellys 24 Bertin Technologies
(Labmakelaar Benelux B.V. Rotterdam, The Netherlands)
using settings: 2x (15 sec, 6500 g, 8°C). Next, total RNA
was isolated using the RNeasy Tissue Mini Kit (Qiagen,
Venlo, The Netherlands) according to manufacturer’s
protocols.
Total RNA was extracted from mouse livers using TRI-
zol reagent (Invitrogen, Breda, The Netherlands), and
purified and DNAse treated using the SV Total RNA Iso-
lation System (Promega, Leiden, The Netherlands).
RNA concentration and purity were assessed spectro-
metrically using a Nano Drop ND-1000 spectrophotom-
eter (Isogen, IJsselstein, The Netherlands). RNA quality
was assessed on an Agilent 2100 bioanalyzer (Agilent
Technologies, Amsterdam, the Netherlands). Only RNA
samples that met quality criteria (i.e. RNA Integrity
Number >8.0) were used for array hybridization experi-
ments. For primary hepatocytes, purified RNA (500 ng)
was used for one cycle cRNA synthesis (Affymetrix,
Santa Clara, CA). Hybridization of samples derived from
primary hepatocytes was performed on Affymetrix Gene
chip mouse genome 430 2.0 arrays. Purified RNA (100
ng) isolated from PCLS was labeled with the Ambion
WT expression kit (Life Technologies, Bleiswijk, The
Netherlands) and hybridized to Affymetrix Mouse Gene
1.1 ST array plate (Affymetrix, Santa Clara, CA). RNA
isolated from mouse livers (5 μg) was used for one cycle
cRNA synthesis (Affymetrix, Santa Clara, CA) and hy-
bridized to Affymetrix Genechip mouse genome 430 2.0
arrays (wildtype and Ppara-KO treated with Wy14643 or
vehicle for 6 hours as well as wildtype and Ppara-KO
treated with Wy14643 or vehicle for 5 days). Hybridiza-
tion, washing, and scanning of all Affymetrix Genechips
was according to standard Affymetrix protocols. Scans of
the Affymetrix arrays were processed using the Biocon-
ductor package [28]. The microarray data obtained from
the above mentioned experiments were deposited to gene
expression omnibus (GEO). The GEO series accession
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numbers are as follows: GSE17250 (primary hepatocytes
obtained from 6 different mouse strains treated with
Wy14643 or vehicle, n = 6 per group), GSE8292 (WT and
Ppara-KO treated with Wy14643 or vehicle for 6 hours,
n = 3-5 per group), and GSE8295 (WT and Ppara-KO
treated with Wy14643 or vehicle for 5 days, n = 4 per
group). The accession number for the microarray of pre-
cision cut liver slices is pending.
Statistical analysis of microarray data
Expression levels of probe sets were calculated using
Robust Multiarray Averaging (RMA) with m-estimator
summarization and remapped in Common Data Format
(CDF) version 17.0.1 [29]. Identification of differentially
expressed genes was performed using Rank Products
(RP). False discovery rates were determined by RP using
1000 permutations of the samples. Genes with a false
discovery rate (FDR) ≤ 0.05 were considered as signifi-
cant [30]. All comparisons were made between treat-
ments and controls (i.e. Wy14643 vs. vehicle).
Gene ontology analysis -DAVID
The significantly up- and down-regulated genes by the
treatments (i.e. Wy14643) were uploaded separately to
the Database for Annotation, Visualization, and Inte-
grated Discovery (DAVID) Bioinformatics Resource. In
DAVID the Functional Annotation Clustering tool gen-
erated clusters of up- or down- overrepresented Gene
Ontology (GO) terms [31,32]. The Mouse Genome 430
2.0 was used as a background for the GO analysis of the
in vitro, ex vivo, and in vivo hepatic models. After correc-
tion for FDR ≤ 0.005 (Benjamini Hochberg), the GO terms
were selected for further analysis and interpretation.
Venn diagram analysis
Venn diagram analysis of the significantly affected genes
identified in our study was performed using VENNY [33].
Pearson’s correlation analysis
Pearson’s correlation analysis was performed using IBM
SPSS Statistics 20 and the results are presented as scat-
terplots using Microsoft Excel 2010.
Results
Identification of differentially expressed genes
In order to identify genes significantly altered by phar-
macological PPARα activation, we analyzed microarray
data of different liver models (i.e. in vitro, ex vivo, and
in vivo) treated with the synthetic PPARα agonist
Wy14643 using Rank Products (RP) [30]. The use of
Wy14643 was justified by the observation that changes
in in vivo hepatic gene expression elicited by Wy14643
and another common PPARα agonist fenofibrate were
extremely similar (Additional file 1). Only genes that
were overlapping between different types of microarray
chips used in our study were included in the analysis. In
general it was observed that the number of significantly
altered genes increased with increasing complexity of
the liver model (with regard to duration of the treatment
and cellular composition of the model) (Figure 1). Thus,
in primary hepatocytes treated with Wy14643 for 6 h
and 24 h, 68 and 93 genes were upregulated, respect-
ively. In liver slices, 117 genes were significantly upregu-
lated by Wy14643, and in livers of mice exposed to
Wy14643 for 6 h and 5 days, 487 and 978 genes were
significantly upregulated, respectively. Very few genes
were downregulated by PPARα activation in primary he-
patocytes, whereas 61, 391 and 794 genes were signifi-
cantly downregulated by Wy14643 treatment in liver
slices, mouse livers treated for 6 h, and mouse livers
treated for 5 days, respectively.
Relevance of in vitro and ex vivo models for the in vivo
situation
To determine the resemblance between “simpler” liver
models (i.e. in vitro and ex vivo) vs. the more complex
models (i.e. in vivo), Venn diagram analysis of genes sig-
nificantly regulated in each model was performed. The
analysis showed that there was a substantial overlap be-
tween the “simpler” hepatic models and the in vivo models,
Figure 2A-C.
Additionally, to evaluate whether Wy14643 affected
gene expression in the same direction in in vitro/ex vivo
versus in vivo models, and to compare the magnitude of
fold changes in each model, Pearson’s correlation ana-
lysis was performed (Figure 3). In the analysis we separ-
ately compared expression changes of genes significantly
upregulated (FDR ≤ 0.05) in primary hepatocytes and
liver slices after Wy14643 treatment with expression
changes of the corresponding genes in vivo. Interest-
ingly, we observed that the majority of the genes ana-
lyzed were commonly upregulated between in vitro/
ex vivo and in vivo experiments. The magnitude of gene
expression changes was generally higher in vivo compared
to in vitro and ex vivo (Figure 3A-F).
The same type of analysis was performed for the sig-
nificantly downregulated genes (FDR ≤ 0.05) identified
ex vivo, i.e. expression of genes significantly downregu-
lated in liver slices was compared with expression
changes of the corresponding genes in vivo. Surprisingly,
out of 61 significantly downregulated genes in liver
slices, only 23 and 31 corresponding genes were changed
in the same direction in livers of mice treated with
Wy14643 for 6 h and 5 days, respectively, while the
remaining genes were unaltered or upregulated in vivo
compared to ex vivo. In general, fold changes of the
commonly downregulated genes were lower in liver
slices compared to livers in vivo (Figure 3G-H). Due to
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the absence of significantly downregulated genes in pri-
mary hepatocytes, no correlation analysis was performed
for this model.
Gene ontology analysis
In order to obtain a comprehensive view of the bio-
logical processes affected by Wy14643 in different liver
models, significantly up- and down-regulated genes were
subjected to GO analysis using DAVID [32,34]. The GO
analysis of the upregulated genes by Wy14643 in all liver
models revealed that several GO terms related to different
aspects of lipid catabolism such as “fatty acid metabolic
process” and “acyl-CoA metabolic process” were signifi-
cantly enriched in almost all hepatic models, except for
“lipid localization” and “peroxisomes organization”, which
were found only in vivo (Figure 4A). However, GO terms
related to cell proliferation/tumorgenesis and other aspects
of lipid metabolism were significantly enriched only in
livers of mice exposed to Wy14643 for 5 days (Figure 4B).
The GO analysis performed for the significantly down-
regulated genes showed that GO terms related to differ-
ent aspects of immunity were significantly enriched in
both ex vivo and in vivo models (Figure 5A). GO terms
exclusively detected in livers of mice exposed to
Wy14643 for 5 days were related to immunity, coagu-
lation, protein/amino acid metabolism, metabolism of
organic compounds as well as GO processes nominated
as “oxidation reduction”. “steroid metabolic process”,
PH 6h PH 24h PCLS 24h L 6h L 5d
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Figure 1 Effect on hepatic gene expression during activation of PPARα. The total number of significantly up- and down-regulated genes
(FDR≤ 0.05) identified in primary hepatocytes treated with Wy14643 for 6 or 24 h (PH 6 h or PH 24 h), precision cut liver slices treated with
Wy14643 for 24 h (PCLS 24 h), livers of mice treated with Wy14643 for 6 h of 5 days (L6h or L5d).
Figure 2 Venn diagram analysis. Venn diagram analysis of the significant genes (FDR≤ 0.05) identified in “simpler” models represented by
(A) primary hepatocytes treated with Wy14643 for 6 h (PH 6 h), (B) primary hepatocytes treated with Wy14643 for 24 h (PH 24 h), and (C) precision cut
liver slices treated with Wy14643 for 24 h (PCLS 24 h) vs. significant genes (rank products, FDR≤ 0.05) identified in in vivo models represented by livers
of mice exposed to Wy14643 for 6 h (L6h) and livers of mice exposed to Wy14643 for 5 days (L5d).
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“hemostasis”, “regulation of body fluid levels”, “bile acid
metabolic process”, “lipid localization”, and “lipid trans-
port” (Figure 5B).
“PPARα-tailored analysis”
Due to the fact that the GO analysis resulted in functional
annotation of only a sub-fraction of the total number of sig-
nificant genes (~25% genes per liver model), an additional
functional analysis, referred to as “PPARα-tailored analysis”,
was performed. The incentive for this additional analysis
was to annotate a higher number of genes than via GO ana-
lysis and assign genes to novel and more detailed functional
categories. The “PPARα-tailored analysis” was performed
gene by gene using the open access database GeneCards.
GeneCards provides current genomic, proteomic, genetic,
transcriptomic, and functional information on all known
and predicted genes. The selection of genes for the
“PPARα-tailored analysis” was rather subjective; we
considered all significant genes that were overlapping be-
tween at least two hepatic models (Figure 6A-B). Eventually
we considered 370 unique upregulated genes (out of 1120
unique genes upregulated in all hepatic models) and 224
unique downregulated genes (out of 991 unique genes
downregulated in all hepatic models). The aim behind such
a selection was to focus on the most relevant genes for
PPARα signaling across all liver models and at the same
time reduce the total number of genes analyzed. We only
analyzed genes that are regulated in a PPARα-dependent
manner. Thus genes that were significantly regulated by
Wy14643 treatment in both wildtype and Ppara-KO were
excluded from the “PPARα-tailored analysis”. Using Gene-
Cards we were able to functionally annotate 227 (out of
370 upregulated) and 125 (out of 224 downregulated)
genes, which were divided into up- and down-regulated
functional categories (Additional files 2, 3 and 4). As part
of the “PPARα-tailored analysis”, genes related to lipid
Figure 3 Pearson’s correlation analysis. Significantly (sig.) upregulated genes (FDR≤ 0.05) identified in primary hepatocytes (PH) treated with
Wy14643 for 6 or 24 h and precision cut liver slices (PCLS) treated with Wy14643 for 24 h were correlated with corresponding genes in livers (L)
of mice treated with Wy14643 for 6 h (A-C) or 5 days (5d), D-F). Significantly downregulated genes (FDR≤ 0.05) identified in PCLS 24 h were
correlated with corresponding genes in L6 h (G) or L5d (H). Each dot represents the average (avg.) log2 value of fold change (FC) in gene
expression of treatment group vs. control. All correlations were significant at P ≤ 0.01, with the exception of 3G and 3H.
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catabolism were categorized into “peroxisomal β-
oxidation”, “peroxisomal membrane & biogenesis”, and
“mitochondrial carriers” and these categories, similarly to
the results from GO analysis, contained significantly up-
regulated genes in all liver models (Additional file 2).
However, the more complex the hepatic model, the
higher the number of significant genes and their fold
change. As in GO analysis, a gene functional category re-
lated to tumorgenesis (i.e. cell cycle) contained genes that
were significantly upregulated only in in vivo models
(Additional file 3).
In comparison to GO analysis, the “PPARα-tailored ana-
lysis” led to the identification of additional upregulated
functional categories such as “extracellular matrix” (ECM),
“cytoskeleton”, “endothelial functions”, “integrity of Golgi”,
“vesicular trafficking”, “endocytosis”, and “neurotransmis-
sion”. Genes belonging to these categories were significantly
upregulated almost exclusively in vivo (Additional files 2
and 3). Downregulated functional categories such as “acute
phase” or “coagulation” contained genes that were signifi-
cantly downregulated mostly in vivo; only few genes within
these categories were also significantly downregulated in
liver slices (e.g. F11, Orm2, Orm3, and Crp) (Additional file
3). In addition, compared to GO analysis, the “PPARα-tai-
lored analysis” identified novel downregulated gene func-
tional categories such as “transcriptional co-repression/
activation”, “NF-κB (downstream activation)”, “immunity”,
“T and B cells functions”, “angiogenesis”, “ECM”, “cytoskel-
eton”, and “neurotransmission”. Genes belonging to these
categories were significantly and nearly exclusively down-
regulated in vivo, with the exception of a few genes that
were also significantly downregulated ex vivo and none of
these genes were significantly altered in vitro (Additional
file 4).
In general, the results of the “PPARα-tailored analysis”
were in line with the statistical and GO analyses and re-
vealed that the most significant changes occurred in vivo,
followed by ex vivo, and the least changes occurred in
in vitro models. However, compared to GO analysis, the
“PPARα-tailored analysis” annotated a higher percentage of
the analyzed genes (i.e. ~50% vs. ~25% respectively) as well
as identified additional and novel PPARα-related functional
categories. A summary of the results of the ‘PPARα- tai-
lored analysis’ is presented in Figure 7.
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Figure 4 Gene Ontology (GO) analysis of significantly upregulated genes in different hepatic models. Significantly (FDR≤ 0.005) enriched
GO terms related to lipid catabolism were identified in most of the liver models studied, A. GO terms related to cell proliferation/tumorgenicity
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Integrated concept of PPARα signaling during its
pharmacological activation
Biological processes identified in the meta-analysis were
integrated into a simplified concept of hepatic PPARα
signaling under not-inflamed conditions (Figure 8). We
propose that during activation of PPARα, significant
regulation of genes related to “ECM” and “cytoskeleton”
as well as “endothelial functions”, “endocytosis”, “Golgi”,
and “vesicular trafficking” might facilitate sudden influx
and traffic of FA to hepatocytes and target organelles
such as nucleus, mitochondria, and peroxisomes. At the
same time, activation of PPARα leads to immunosup-
pression caused by downregulation of genes related to
“NF-κB signaling”, “coagulation”, “acute phase”, and “im-
munity”, likely to suppress an immune response elicited
by massive traffic of potentially cytotoxic FA [35]. Fi-
nally, pharmacological activation of PPARα affects genes
involved in “neurotransmission”.
Discussion
The challenge in meta-analyses is to circumvent the
variation of independent microarray experiments and
extract biologically relevant information [36]. The meta-
analysis of hepatic PPARα signaling performed in our
study is mostly based on separate microarray experi-
ments that were generated over several years and origin-
ally served a different purpose than this study [25,27].
Variations in the experimental set up used to generate
these microarray data are: use of different types of Affyme-
trix gene chips, different batches of chemicals, unequal
number of biological replicates per group, differences in
time of exposure to Wy14643 and model-specific concen-
tration of Wy14643. Furthermore, there were differences
related to age, gender, and mouse strains, which all to-
gether could increase experimental variation and hamper
the identification of genuine biological effects. However,
the experiments were performed on the same platform, by
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Figure 5 Gene Ontology (GO) analysis of significantly downregulated genes in different hepatic models. Significantly (FDR≤ 0.005)
enriched GO terms related to different aspects of immunity were identified in liver slices treated with Wy14643 for 24 h (PCLS 24 h) and livers of
mice treated with Wy14643 for 6 h (L6h) or 5 days (L5d), A. GO terms related to other aspects of immunity, coagulation, protein/amino acid (aa)
metabolism, metabolism of organic compounds, and others were significantly (FDR≤ 0.005) enriched only in livers of mice treated with Wy14643
for 5 days (L5d), B.
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the same technician, and standard procedures were used
over the years.
To minimize the effects of the above-mentioned experi-
mental differences, and to allow identification of biologic-
ally relevant significant genes, we applied the RP approach.
The RP approach is a powerful statistical method to analyze
microarray data generated from relatively few replicates,
performed in different laboratories and/or using different
platforms. Moreover, RP outperformed other statistical tests
applied in meta-analyses such as t-based approach and
Fisher’s Inverse χ2 method [30,36,37].
In our study, we identified a variable number of sig-
nificantly up- and down-regulated genes in different liver
models. The number of significantly regulated genes cor-
responded with the complexity of the hepatic model de-
termined by time of exposure, cellular composition, and
the absence/presence of systemic effects (i.e. inter-organ
interactions). Thus, the lowest number of significantly
upregulated genes was found in primary hepatocytes and
in this model very few genes were significantly downreg-
ulated. This finding contradicts with our previous ana-
lysis in which we identified more than 400 up- and
down-regulated genes in primary hepatocytes after 6 and
24 h treatment with Wy14643 [25]. This discrepancy
can be explained by the application of different statistical
methods in both studies, i.e. the former study used a
Linear Models for Microarray Data without correction
for FDR. In contrast, we applied a more stringent RP
that corrects for FDR [25,28,30].
The very low number of downregulated genes in pri-
mary hepatocytes may be explained by the absence of
the non-parenchymal fraction, which is an abundant
source of pro-inflammatory factors [38]. Although it was
shown that activation of PPARα can suppress the im-
mune response and downregulate gene expression in
hepatocytes by antagonizing the NF-κB signaling path-
way, the relevant experiments were performed in the
presence of pro-inflammatory stimuli [14]. In contrast,
our experiments in hepatocytes were performed under
non-inflamed conditions, which may explain the very
low number of significantly downregulated genes. In
agreement with our results, a study performed in rat
liver and rat primary hepatocytes treated with PPARα li-
gands showed that downregulation of (proinflammatory)
genes occurred only in vivo [39].
In order to evaluate the relevance of in vitro and
ex vivo models for the in vivo situation, we performed a
comparative analysis of the significantly altered genes in
each model by means of Venn diagrams. In addition,
Pearson’s correlation analysis was performed to compare
the direction of changes in gene expression in in vitro
and ex vivo models vs. the in vivo situation. The results
of Venn diagram analysis showed substantial similarities
between “simpler” liver models and the in vivo models,
suggesting that primary hepatocytes and liver slices are
relevant models to study pharmacological activation of
PPARα in vivo. With regard to the results of Pearson’s
correlation analysis, it revealed that almost all genes up-
regulated in vitro and ex vivo, were also upregulated
in vivo. In contrast, only a small fraction of genes down-
regulated ex vivo was downregulated in vivo. These re-
sults indicate that primary hepatocytes and liver slices
are valid liver models to study genes induced by activa-
tion of PPARα with Wy14643, but less suitable to study
genes downregulated by activation of PPARα with
Wy14643. This finding was unexpected and suggests that
downregulation of genes by PPARα is model-dependent.
Inasmuch as the cellular composition of liver slices is
comparable to the liver in vivo, i.e. both models contain
parenchymal and non-parenchymal cells [40], these
Figure 6 Gene selection for the “PPARα tailored analysis”. Genes selected for the “PPARα tailored analysis” consisted of significantly up- and
down-regulated genes (FDR≤ 0.05) that were overlapping between at least two liver models. Numbers of overlapping up- and down-regulated
genes are presented in A and B respectively. PH 6 h/24 h stands for primary hepatocytes treated with Wy14643 for 6 or 24 h, PCLS 24 h-precision
cut liver slices treated with Wy14643 for 24 h, and L6 h/5d-liver treated with Wy14643 for 6 h of 5 days.
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differences may be explained by systemic effects that are
obviously absent ex vivo.
In all liver models, lipid metabolism emerged as a
dominant pathway regulated by PPARα [25,27]. Despite
the fact that there is a cross-talk between parenchymal
and non-parenchymal fractions in regulation of hepatic
lipid metabolism [41-43], we did not observe striking
differences in regulation of genes involved in lipid me-
tabolism between our in vitro and ex vivo models,
suggesting that the presence of non-parenchymal cells
does not affect the Wy14643-mediated regulation of
genes involved in lipid metabolism. Genes related to
lipid metabolism were induced most significantly (in
terms of number and fold change) in vivo, indicating
that lipid metabolism is more sensitive to regulation
in vivo compared to in vitro and ex vivo models. How-
ever, it can’t be ruled out that our results are biased by
the lack of standardization of conditions across all liver
-42 -32 -22 -12 -2 8 18 28
Number of signiﬁcantly up- or down-regulated genes 
in vivo
ex vivo
in vitro
Peroxisomes
Mitochondria
Microsomal 
Glycogenolysis & gluconeogenesis
transporter
metabolism
of metabolism
Lipid turnover
factors
ECM (up)
Cytoskeleton (up)
Endothelial 
Immunity
Vesicular traﬃcking
Neurotransmision (up)
Cell cycle
al co-repression
al 
Immunity
ECM (down)
Cytoskeleton (down)
Transporters & vesicular 
traﬃcking
Metabolism of aa
Steroid metabolism
Lipogenesis
Phase I &II of drug metabolism
Neurotransmission (down)
Figure 7 Summary of the “PPARα tailored analysis”. Genes selected for the “PPARα-tailored analysis” were annotated using GeneCards and
grouped into functional categories such as “peroxisomes”, “mitochondria” etc. The total number of significantly up- and down-regulated genes
found per category in in vitro, ex vivo, and in vivo models is represented by horizontal bars. Bars located >0 on Y axis show number of upregulated
genes and bars located <0 on Y axis show number of downregulated genes. In vitro represents primary hepatocytes treated with Wy14643 for 24 h,
ex vivo - precision cut liver slices treated with Wy14643 for 24 h and in vivo - livers of mice treated with Wy14643 for 5 days.
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models in relation to differences in concentration of glu-
cose, insulin, or other biomolecules, which could also
affect lipid metabolism.
Next to the identification of processes related to differ-
ent aspects of lipid catabolism, the “PPARα-tailored ana-
lysis” identified genes, mostly in vivo, that could be
assigned into novel functional categories not previously
linked to PPARα, such as “ECM”, “cytoskeleton”, “endo-
thelial functions”, “integrity of Golgi”, “vesicular traffick-
ing”, and “endocytosis”. Given the key role of PPARα in
regulation of hepatic lipid metabolism, we hypothesize
that genes belonging to these novel categories might
somehow be linked to transport, traffic, and catabolism
of FA during activation of PPARα by Wy14643. It is pos-
sible that during pharmacological activation of PPARα, FA
and TG carried by lipoproteins and albumin freely pass
fenestrated hepatic endothelial cells [27,44]. In hepato-
cytes, FA are taken up by transporters [45], followed by
poorly defined trafficking of FA to target organelles such
as mitochondria and peroxisomes to undergo oxidation.
Consistent with this picture, we hypothesize that genes
categorized as “endothelial functions” and “endocytosis”
could be involved in transfer of FA through the endothe-
lium, exemplified by the known PPARα target Angptl4,
which plays a role in vascular permeability [46]. In
addition, Adtrp, Nrpt, E2f8 could also modulate endothe-
lial permeability via interaction with Vegf-b [47]. Next, the
traffic of FA to target organelles might be governed by
genes in categories denoted as “ECM”, “cytoskeleton”,
“integrity of Golgi”, “endocytosis”, and “vesicular traffick-
ing”. This notion is in line with an emerging concept of
vesicular transport of FA to target organelles and cells
co-occurring with reorganization of ECM, cytoskeleton,
and Golgi [48]. Interestingly, similar functional categories
have been linked to PPARβ/δ in pancreatic β–cells includ-
ing granule biosynthesis, intra-cellular vesicle trafficking,
and exocytosis [49]. Therefore, it could be hypothesized
that all PPARs may play a role in traffic of certain mole-
cules in and out of the cell.
In addition to the above mentioned processes, several
GO processes and genes related to different aspects of
immunity were significantly downregulated only in
ex vivo and in vivo models (Figure 5, Additional file 3).
These findings are in concordance with the known anti-
Figure 8 An integrated picture of PPARα biology. Gene functional categories identified in the “PPARα tailored analysis” were integrated into a
simplified concept of hepatic PPARα biology. The picture represents a hepatocyte and organelles such as lipid droplets (yellow spheres), Golgi,
transport vesicles (irregular blue spheres), nucleus, mitochondria, peroxisomes (regular light blue spheres), and trafficking FFA (black figures
symbolizing hydrophobic and hydrophilic parts of FFA). Text boxes contain the identified functional categories and arrows indicate direction of
changes of the significant genes (FDR≤ 0.05) within the gene functional categories.
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inflammatory properties of PPARα [11,14]. However, in
our study, due to the lack of inflammation, it seems to
be more appropriate to refer to these processes as im-
munosuppression. Immunosuppression was not observed
in primary hepatocytes, suggesting that interaction with
immune mediators and/or immune cells (e.g. Kupffer
cells) is essential.
Another novel gene functional category identified in
this study exclusively in vivo is denoted as “neurotrans-
mission”. Currently, there is a scarce evidence for a
crosstalk between PPARα and the nervous system. How-
ever, recently it was shown that stimulation of the vagus
nerve increased plasma endogenous PPARα ligands co-
occurring with upregulation of hepatic PPARα expression
and systemic anorectic effects [50]. Another study showed
that hepatic PPARα activation led to glucocorticoid-
induced insulin resistance and hypertension via an afferent
vagal nerve pathway [51]. It is possible, therefore, that acti-
vation of PPARα by Wy14643 affects neurosignaling to
coordinate liver metabolism with other organs and tissues
to maintain energy homeostasis.
Finally, in accordance with the known hepatocarcino-
genic effect of peroxisomes proliferators in rodents [52],
we found that activation of PPARα significantly upregu-
lated several genes related to cell proliferation in vivo.
Surprisingly, this effect was absent in our in vitro and
ex vivo liver models. Given the fact that Wy14643 in-
duces DNA synthesis in rat hepatocytes after 48 hours,
but not 24 hours [53], it can be speculated that the 24
hours Wy14643 treatment in our in vitro model might
be too short to detect the proliferative/carcinogenic
changes. Previously it was reported that treatment of
mouse primary hepatocytes with peroxisomes prolifera-
tors (including Wy14643) for 24 hours led to upregula-
tion of 11 genes related to liver cancer (i.e. Angptl4,
Bnip3, Dbi, Fabp1, Fabp2, Fasn, HifIa, Lgals3, Ly6d,
Mgll, SerpineI) [54]. However, it has to be stressed that
none of these genes is strictly related to cell proliferation/
carcinogenesis [GeneCards]. Consistent with the notion
that Kupffer cells play a central role in peroxisome
proliferator-induced carcinogenesis, it was found that
genes related to cell proliferation are induced by PPARα li-
gands in rat liver but not in primary rat hepatocytes [39].
Our observation that treatment of liver slices with
Wy14643 did not alter genes related to cell proliferation
conflicts with the finding that peroxisomes proliferators
induced DNA synthesis in rodent co-cultures of hepato-
cytes with non-parenchymal cells [41,53]. A possible ex-
planation for this discrepancy might be that to assess
proliferative/carcinogenic properties of peroxisomes pro-
liferators, measuring DNA synthesis is more appropriate
than analysis of genes related to cell proliferation. Unfor-
tunately, we cannot make a comparison of our gene ex-
pression data obtained in liver slices with gene expression
obtained in other relevant rodent liver models, due to the
lack of such data.
Conclusions
In summary, this study provides a comprehensive pic-
ture of gene expression during pharmacological activa-
tion of PPARα by Wy14643 in different mouse hepatic
models under not-inflamed conditions. PPARα-dependent
regulation of many genes and processes involved in lipid
metabolism is mostly independent of the presence of non-
parenchymal cells or inter-organ interactions, as it was
observed in all liver models. PPARα-dependent regulation
of inflammatory genes requires the presence of non-
parenchymal cells, because it was observed only ex vivo
and in vivo. However, the full spectrum of PPARα biology
at the level of lipid metabolism, immunity, carcinogenesis,
as well as novel aspects of PPARα signaling such as coagu-
lation, vesicular trafficking and the extracellular matrix,
seems to require systemic factors, as it was observed ex-
clusively in vivo.
Although in vitro and ex vivo systems turned out to
be relevant liver models to study the PPARα transcrip-
tome compared to the in vivo situation, liver slices be-
haved as an intermediate model between in vitro and
in vivo, and thus represent a superior replacement for
primary hepatocytes.
Additional files
Additional file 1: A comparative analysis of gene expression by
Wy14643 and fenofibrate in mouse liver. Global gene expression data
obtained from samples representing livers of mice treated for 6 h with
Wy14643 or fenofibrate were expressed as fold change calculated as ratio
of gene expression in treatment group (n=4 or 5) vs. gene expression in
control group (n=4).
Additional file 2: PPARα tailored gene functional analysis
(upregulation). Significantly upregulated genes that were overlapping
between at least two hepatic models were selected for a functional
analysis using an open access database GeneCards. Based on the
provided information, the selected genes were grouped into functional
categories and analyzed in each hepatic model i.e. primary hepatocytes
treated with Wy14643 for 6 h or 24 h (PH 6H or PH 24 h), precision cut
liver slices treated with Wy14643 for 24 h (PCLS 24 h), and livers of mice
treated with Wy14643 for 6h or 5 days (L6h or L5d). Genes that were
significantly altered are depicted in bold and underlined, red color
indicates upregulation, black no change, and green downregulation of
gene expression. Fold change was calculated as the average gene
expression value in treatment group vs. control.
Additional file 3: PPARα tailored gene functional analysis
(upregulation). Significantly upregulated genes that were overlapping
between at least two hepatic models were selected for a functional
analysis using an open access database GeneCards. Based on the
provided information, the selected genes were grouped into functional
categories and analyzed in each hepatic model i.e. primary hepatocytes
treated with Wy14643 for 6h or 24 h (PH 6H or PH 24 h), precision cut
liver slices treated with Wy14643 for 24 h (PCLS 24 h), and livers of mice
treated with Wy14643 for 6 h or 5 days (L6h or L5d). Genes that were
significantly altered are depicted in bold and underlined, red color
indicates upregulation, black no change, and green downregulation of
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gene expression. Fold change was calculated as the average gene
expression value in treatment group vs. control.
Additional file 4: PPARα tailored gene functional analysis
(downregulation). Significantly downregulated genes that were
overlapping between at least two hepatic models were selected for a
functional analysis using an open access database GeneCards. Based on
the provided information, the selected genes were grouped into
functional categories and analyzed in each hepatic model i.e. primary
hepatocytes treated with Wy14643 for 6 h or 24 h (PH 6H or PH 24 h),
precision cut liver slices treated with Wy14643 for 24h (PCLS 24 h), livers
of mice treated with Wy14643 for 6 h or 5 days (L6h or L5d). Genes that
were significantly altered are in bold and underlined, red color indicates
upregulation, black no change, and green downregulation. Fold change
was calculated as the average gene expression value in treatment group
vs. control.
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